Past RFP
GHIT Fund RFP Hit-to-Lead Platform 2024-001
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release January 12, 2024
Intent to Apply No later than 10:00 am Tokyo time on February 13, 2024
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2024-001_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on March 6, 2024
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2024-001_Questions
Full Proposal Due No later than 10:00 am Tokyo time on March 13, 2024
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2024-001_Proposal
Proposals Evaluation and Interview Processes March 2024 – June 2024
Notification of Results July 2024
Investment Agreement Fully Executed (Awarded Proposals) August 2024
GHIT Fund RFP Hit-to-Lead Platform 2023-002
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release July 24, 2023
Intent to Apply No later than 10:00 am Tokyo time on August 28, 2023
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2023-002_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on September 25, 2023
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2023-002_Questions
Full Proposal Due No later than 10:00 am Tokyo time on October 2, 2023
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2023-002_Proposal
Proposals Evaluation and Interview Processes October 2023 - February 2024
Notification of Results February 2024
Investment Agreement Fully Executed (Awarded Proposals) March 2024
GHIT Fund RFP Hit-to-Lead Platform 2023-001
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release January 11, 2023
Intent to Apply No later than 10:00 am Tokyo time on February 10, 2023
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2023-001_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on March 3, 2023
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2023-001_Questions
Full Proposal Due No later than 10:00 am Tokyo time on March 17, 2023
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2023-001_Proposal
Proposals Evaluation and Interview Processes March 2023 – June 2023
Notification of Results July 2023
Investment Agreement Fully Executed (Awarded Proposals) August 2023
GHIT Fund RFP Hit-to-Lead Platform 2022-002
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release July 26, 2022
Intent to Apply No later than 10:00 am Tokyo time on August 31, 2022
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2022-002_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on September 22, 2022
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2022-002_Questions
Full Proposal Due No later than 10:00 am Tokyo time on September 30, 2022
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2022-002_Proposal
Proposals Evaluation and Interview Processes September 2022 - January 2023
Notification of Results February 2023
Investment Agreement Fully Executed (Awarded Proposals) March 2023
GHIT Fund RFP Hit-to-Lead Platform 2022-001
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release January 12, 2022
Intent to Apply No later than 10:00 am Tokyo time on February 9, 2022
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2022-001_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on March 9, 2022
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2022-001_Questions
Full Proposal Due No later than 10:00 am Tokyo time on March 16, 2022
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2022-001_Proposal
Proposals Evaluation and Interview Processes March 2022 – June 2022
Notification of Results July 2022
Investment Agreement Fully Executed (Awarded Proposals) August 2022
GHIT Fund RFP Hit-to-Lead Platform 2021-002
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release August 2, 2021
Intent to Apply No later than 10:00 am Tokyo time on September 15, 2021
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2021-002_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on October 15, 2021
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2021-002_Questions
Full Proposal Due No later than 10:00 am Tokyo time on October 22, 2021
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2021-002_Proposal
Proposals Evaluation and Interview Processes October 2021 – February 2022
Notification of Results February 2022
Investment Agreement Fully Executed (Awarded Proposals) March 2022
GHIT Fund RFP Hit-to-Lead Platform 2021-001
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release January 12, 2021
Intent to Apply No later than 10:00 am Tokyo time on February 15, 2021
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2021-001_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on March 8, 2021
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2021-001_Questions
Full Proposal Due No later than 10:00 am Tokyo time on March 15, 2021
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2021-001_Proposal
Proposals Evaluation and Interview Processes March 2021 – June 2021
Notification of Results July 2021
Investment Agreement Fully Executed (Awarded Proposals) August 2021
GHIT Fund RFP Hit-to-Lead Platform 2020-002
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release August 3, 2020
Intent to Apply No later than 10:00 am Tokyo time on September 3, 2020
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2020-002_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on September 28, 2020
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2020-002_Questions
Full Proposal Due No later than 10:00 am Tokyo time on October 5, 2020
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2020-002_Proposal
Proposals Evaluation and Interview Processes October 2020 – February 2021
Notification of Results February 2021
Investment Agreement Fully Executed (Awarded Proposals) March 2021
GHIT Fund RFP Hit-to-Lead Platform 2020-001
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release January 14, 2020
Intent to Apply No later than 10:00 am Tokyo time on February 28, 2020
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2020-001_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on March 24, 2020
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2020-001_Questions
Full Proposal Due No later than 10:00 am Tokyo time on March 31, 2020
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2020-001_Proposal
Proposals Evaluation and Interview Processes March 2020 – July 2020
Notification of Results July 2020
Investment Agreement Fully Executed (Awarded Proposals) August 2020
GHIT Fund RFP Hit-to-Lead Platform 2019-002
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release August 1, 2019
Intent to Apply No later than 10:00 am Tokyo time on September 2, 2019
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2019-002_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on September 25, 2019
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2019-002_Questions
Full Proposal Due No later than 10:00 am Tokyo time on October 1, 2019
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2019-002_Proposal
Proposals Evaluation and Interview Processes October 2019 – February 2020
Notification of Results February 2020
Investment Agreement Fully Executed (Awarded Proposals) March 2019
GHIT Fund RFP Hit-to-Lead Platform 2019-001
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release February 1, 2019
Intent to Apply No later than 10:00 am Tokyo time on March 1, 2019
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2019-001_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on March 25, 2019
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2019-001_Questions
Full Proposal Due No later than 10:00 am Tokyo time on April 1, 2019
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2019-001_Proposal
Proposals Evaluation and Interview Processes April 2019 – July 2019
Notification of Results July 2019
Investment Agreement Fully Executed (Awarded Proposals) August 2019
GHIT Fund RFP Hit-to-Lead Platform 2018-002
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release August 1, 2018
Intent to Apply No later than 10:00 am Tokyo time on September 3, 2018
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-002_Intent to ApplyQ&A
(RFP related questions)No later than 10:00 am Tokyo time on September 26, 2018
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-002_QuestionsFull Proposal Due No later than 10:00 am Tokyo time on October 3, 2018
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-002_ProposalProposals Evaluation and Interview Processes October 2018 - February 2019
Notification of Results February 2019
Investment Agreement Fully Executed (Awarded Proposals) March 2019
GHIT Fund RFP Hit-to-Lead Platform 2018-001
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release June 8, 2018
Intent to Apply No later than 10:00 am Tokyo time on June 15, 2018
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-001_Intent to ApplyQ&A
(RFP related questions)No later than 10:00 am Tokyo time on June 22, 2018
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-001_QuestionsFull Proposal Due No later than 10:00 am Tokyo time on June 29, 2018
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2018-001_ProposalProposals Evaluation and Interview Processes July 2018
Notification of Results July 2018
Investment Agreement Fully Executed (Awarded Proposals) August 2018
GHIT Fund RFP Hit-to-Lead Platform 2017-001
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release July 25, 2017
Intent to Apply No later than 10:00 am Tokyo time on September 1, 2017
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2017-001_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on September 20, 2017
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2017-001_Questions
Full Proposal Due No later than 10:00 am Tokyo time on October 2, 2017
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2017-001_Proposal
Proposals Evaluation and Interview Processes October 2017 - January 2018
Notification of Results February 2018
Investment Agreement Fully Executed (Awarded Proposals) March 2018
GHIT Fund RFP Hit-to-Lead Platform 2016-002
The Hit-to-Lead Platform (HTLP) is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
HTLP projects will focus on the aspect of the drug discovery and development process that progresses hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. This platform will provide a bridge from early drug discovery to our product development platform that begins with the lead-optimization step.
The key requirement of the Hit-to-Lead Platform is to convert drug hits originated from Japanese compound libraries into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behavior, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
Interested applicants can find detailed information on the RFP and the Intent to Apply (ITA) form below. An ITA should be submitted first and upon an eligibility assessment, approved applicants will be notified and request to submit a full proposal to the GHIT Fund.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release August 1, 2016
Intent to Apply No later than 10:00 am Tokyo time on September 1, 2016
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2016-002_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on September 20, 2016
Submit RFP questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2016-002_Questions
Full Proposal Due No later than 10:00 am Tokyo time on October 3, 2016
Submit proposal to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2016-002_Proposal
Proposals Evaluation and Interview Processes October 2016 - January 2017
Notification of Results No later than February 1, 2017
Investment Agreement Fully Executed (Awarded Proposals) No later than March 31, 2017
GHIT Fund RFP Hit-to-Lead Platform 2016-001
The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.
If you are interested in applying for the platform, please see RFP.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release February 26, 2016
Intent to Apply No later than 10:00 am Tokyo time on March 28, 2016
Submit Intent to Apply form to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2016-001_Intent to Apply
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on April 18, 2016
Submit questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-HTLP-2016-001_Questions
Full Proposal Due No later than 10:00 am Tokyo time on April 27, 2016
Submit proposal to HTLPResponse@ghitfund.org Email
Subject Line: GHIT-RFP-HTLP-2016-001_Proposal
Notification of Results No later than August 1, 2016
GHIT Fund RFP Hit-to-Lead Platform 2015-002
The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.
If you are interested in applying for the platform, please see RFP.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release August 12, 2015
Intent to Apply No later than 10:00 am Tokyo time on October 5, 2015Submit Intent to Apply form to HTLPResponse@ghitfund.orgEmail Subject Line: GHIT-RFP-HTLP-2015-002_Intent to ApplyQ&A
(RFP related questions)No later than 10:00 am Tokyo time on November 2, 2015Submit questions to HTLPResponse@ghitfund.orgEmail Subject Line: GHIT-RFP-HTLP-2015-002_Questions Full Proposal Due No later than 10:00 am Tokyo time on November 9, 2015Submit questions to HTLPResponse@ghitfund.orgEmail Subject Line: GHIT-RFP-HTLP-2015-002_ProposalNotification of Results No later than February 1, 2016
Investment Agreement :No later than March 1, 2016
GHIT Fund RFP Hit-to-Lead Platform 2015-001
The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.
If you are interested in applying for the platform, please see RFP.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release February 6, 2015
Intent to Apply No later than 10:00 am Tokyo time on March 20, 2015Submit Intent to Apply form to HTLPResponse@ghitfund.orgEmail Subject Line: GHIT-RFP-HTLP-2015-001_Intent to ApplyQ&A
(RFP related questions)No later than 10:00 am Tokyo time on April 13, 2015Submit questions to HTLPResponse@ghitfund.orgEmail Subject Line: GHIT-RFP-HTLP-2015-001_Questions Full Proposal Due No later than 10:00 am Tokyo time on April 20, 2015Submit proposal to HTLPResponse@ghitfund.orgEmail Subject Line: GHIT-RFP-HTLP-2015-001_Proposal Notification of Results No later than August 1, 2015
GHIT Fund RFP Hit-to-Lead Platform 2014-002
The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release August 6, 2014
Intent to Apply 10:00 am September 10, 2014
Submit GHIT_HTLP_RFP2014-002_Intent_To_Apply.docx to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-002 Intent to Apply
Q&A
(RFP related questions)Submit Questions to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-002 Questions
Full Proposal Due 10:00 am Tokyo Time October 10, 2014
Submit GHIT Fund HTLP Proposal, Timeline and Budget templates to HTLPResponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-002 Proposal
Notification of Results No later than January 31, 2015
GHIT Fund RFP Hit-to-Lead Platform 2014-001
The GHIT Fund endeavors to further facilitate collaboration & funding of global health technology R&D, to build momentum, and to demonstrate action and results. The Hit-to-Lead Platform (HTLP) is designed to leverage the Product Development Partnerships (PDPs)’ active platform for neglected and tropical diseases in partnership with Japanese companies or academic organizations that have relevant compounds. The intention is to facilitate access to the chemical diversity in Japanese research organizations and to the medicinal chemistry expertise in Japan.
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release March 17, 2014
Intent to Apply 10:00 am April 04, 2014
Submit GHIT Fund HTLP RFP2014-001 Intent To Apply to HTLPresponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-001 Intent to ApplyQ&A
(RFP related questions)Submit Questions to HTLPresponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-001 QuestionsFull Proposal Due 10:00 am Tokyo Time April 30, 2014
Submit GHIT Fund HTLP RFP2014-001 to HTLPresponse@ghitfund.org
Email Subject Line: GHIT-HTLP_RFP-2014-001 ProposalNotification of Results No later than July 15, 2014